ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Imbalance of T cell subsets: a core event that mediates the progression of T2DM and its complications.Frontiers in immunology · 2025Review
- Effects of 8 weeks of moderate physical training on body composition, lipid profile, inflammatory markers, and physical activity in middle aged females.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Interleukin-22 (IL-22) has been demonstrated to be involved in the regulation of glucose metabolism, insulin resistance and inflammation response, which indicates that IL-22 might be associated with the occurrence and progression of diabetes. This study aimed to assess serum IL-22 levels in participants with type 2 diabetes mellitus (T2DM) and analyze the association between IL-22 levels and T2DM risk. Methods: Serum IL-22 concentrations of recruited healthy participants (n=48), newly diagnosed T2DM participants (n=46), and T2DM participants receiving placebo (n=7) or dipeptidyl peptidase-4 inhibitors (DPP-4i) sitagliptin monotherapy (n=7) were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Mice fed a high-fat diet (HFD) were administered sitagliptin and evaluated for IL-22 and intestinal inflammation-related indicators. Results: Serum IL-22 levels were higher in the T2DM group (127.16 ± 75.35) than in healthy controls (69.18 ± 32.83, Conclusion: Serum IL-22 is a significant independent risk factor for T2DM, implying that circulating IL-22 may be a predictive biomarker and therapeutic target for T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.